
AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company functions across several vital therapeutic areas like immunology, oncology, neuroscience, eye care, virology, and gastroenterology.
Recently, many of ABBV’s drugs got approved by major regulatory bodies, which are being held in very high regard. On July 26, 2022, ABBV announced that the European Commission approved the company’s RINVOQ® (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of active ulcerative colitis in adults.